OBJECTIVE: To study the immunogenicity and tolerability of Haemophilus influenzae type b (Hib) conjugate vaccine administered in the neonatal period. DESIGN: Hib capsular polysaccharide (PS)-tetanus toxoid conjugate vaccine (PRP-T) was given to 120 neonates at 2 days of age, followed by PRP-T or the Hib PS vaccine at 4 months and a PRP-T booster at 14 months. Their anti-Hib PS concentrations were compared with those in children receiving PRP-T at 2 and 4 months or at 4 months. RESULTS: No serious adverse reactions were noted. The geometric mean concentration of anti-Hib PS at the age of 2 days was 0.34 micrograms/mL and at 4 months was 0.12 micrograms/mL. This was significantly more than the concentration in unimmunized infants at this age and 3.5 times more than expected, taking into account the natural decay of transplacentally acquired antibodies. Such a response was not seen in infants with a high (greater than 3.0 micrograms/mL) neonatal antibody concentration. The PRP-T vaccine given at 4 months elicited an antibody response in all infants and Hib PS in 62%, indicating immunologic priming. At 14 months, a higher percentage of the infants who had received PRP-T at 2 days and 4 months than of those who had received PRP-T at 4 months only had anti-Hib PS concentrations greater than 0.15 micrograms/mL. All infants responded well to the booster at 14 months. There was no evidence of immunologic tolerance. CONCLUSIONS: Neonatal immunization with PRP-T was safe and well tolerated in Finnish infants, and it would be worthwhile to further study its effects in higher risk populations.
OBJECTIVE: To study the immunogenicity and tolerability of Haemophilus influenzae type b (Hib) conjugate vaccine administered in the neonatal period. DESIGN: Hib capsular polysaccharide (PS)-tetanus toxoid conjugate vaccine (PRP-T) was given to 120 neonates at 2 days of age, followed by PRP-T or the Hib PS vaccine at 4 months and a PRP-T booster at 14 months. Their anti-Hib PS concentrations were compared with those in children receiving PRP-T at 2 and 4 months or at 4 months. RESULTS: No serious adverse reactions were noted. The geometric mean concentration of anti-Hib PS at the age of 2 days was 0.34 micrograms/mL and at 4 months was 0.12 micrograms/mL. This was significantly more than the concentration in unimmunized infants at this age and 3.5 times more than expected, taking into account the natural decay of transplacentally acquired antibodies. Such a response was not seen in infants with a high (greater than 3.0 micrograms/mL) neonatal antibody concentration. The PRP-T vaccine given at 4 months elicited an antibody response in all infants and Hib PS in 62%, indicating immunologic priming. At 14 months, a higher percentage of the infants who had received PRP-T at 2 days and 4 months than of those who had received PRP-T at 4 months only had anti-Hib PS concentrations greater than 0.15 micrograms/mL. All infants responded well to the booster at 14 months. There was no evidence of immunologic tolerance. CONCLUSIONS: Neonatal immunization with PRP-T was safe and well tolerated in Finnish infants, and it would be worthwhile to further study its effects in higher risk populations.
Authors: Julie Rowe; Stephanie T Yerkovich; Peter Richmond; Devinda Suriyaarachchi; Elizabeth Fisher; Leonie Feddema; Richard Loh; Peter D Sly; Patrick G Holt Journal: Infect Immun Date: 2005-12 Impact factor: 3.441
Authors: J Anthony G Scott; John Ojal; Lindsey Ashton; Anne Muhoro; Polly Burbidge; David Goldblatt Journal: Clin Infect Dis Date: 2011-08-23 Impact factor: 9.079
Authors: Donald Waters; Issrah Jawad; Aziez Ahmad; Ivana Lukšić; Harish Nair; Lina Zgaga; Evropi Theodoratou; Igor Rudan; Anita K M Zaidi; Harry Campbell Journal: J Glob Health Date: 2011-12 Impact factor: 4.413
Authors: Anita H J van den Biggelaar; Peter C Richmond; William S Pomat; Suparat Phuanukoonnon; Marie A Nadal-Sims; Catherine J Devitt; Peter M Siba; Deborah Lehmann; Patrick G Holt Journal: Vaccine Date: 2009-01-14 Impact factor: 3.641